ArticleOncology letters2015
microRNA-126 suppresses PAK4 expression in ovarian cancer SKOV3 cells.
Article in Oncology letters, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- Potential role of microRNA-126 in the diagnosis of cancers: A systematic review and meta-analysis.Medicine · 2016Pooled it
- Exosomal microRNAs as tumor markers in epithelial ovarian cancer.Molecular oncology · 2018Trial
- P21-activated kinase 4: a potent oncogene, molecular mechanisms and opportunities for targeted therapy.Cancer cell international · 2025Review
- Gene Therapy for Malignant and Benign Gynaecological Disorders: A Systematic Review of an Emerging Success Story.Cancers · 2022Review
- LINC01224 Exhibits Cancer-Promoting Activity in Epithelial Ovarian Cancer Through microRNA-485-5p-Mediated PAK4 Upregulation.OncoTargets and therapy · 2020Article
- MicroRNA in Ovarian Cancer: Biology, Pathogenesis, and Therapeutic Opportunities.International journal of environmental research and public health · 2019Review
- MicroRNA-126 affects ovarian cancer cell differentiation and invasion by modulating expression of vascular endothelial growth factor.Oncology letters · 2018Article
- Identification and validation of potential prognostic and predictive miRNAs of epithelial ovarian cancer.PloS one · 2018Article
- Upregulation of microRNA-18b induces phosphatase and tensin homolog to accelerate the migration and invasion abilities of ovarian cancer.Oncology letters · 2017Article
- Effect of integrin‑linked kinase gene silencing on microRNA expression in ovarian cancer.Molecular medicine reports · 2017Article
- Human mesenchymal stem cell homing induced by SKOV3 cells.American journal of translational research · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary ovarian cancer is one of the predominant causes of mortality from gynecological cancer. The suppression of serine/threonine p21-activated kinases (PAKs), proteins involved in cell morphology and cytoskeletal reorganization, has been hypothesized to improve the survival of patients with ovarian cancer. However, the association between microRNA-126 (miR-126) and PAK4 in the inhibition of ovarian cancer cell invasion remains to be established. The present study demonstrated changes in the level of PAK4 expression in ovarian cancer SKOV3 cells with altered miR-126 compared with normal SKOV3 cells. The SKOV3 cells that were transfected with LV3-miR-126 to increase miR-126 expression exhibited significantly downregulated expression levels of PAK4 (P<0.05), whilst transfection with the LV3-hsa-miR-126 inhibitor increased the expression of PAK4 in these cells (P<0.05), as assessed by immunofluorescence staining. Furthermore, western blot analysis revealed a significant increase in PAK4 expression in the SKOV3 cells transfected with the LV3-hsa-miR-126 inhibitor, and a decrease in those transfected with LV3-hsa-miR-126. The present study provides an experimental foundation for miR-126 as a potential tumor suppressor that may decrease PAK4 expression to inhibit ovarian cancer cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.